unclear how FOXA1 loss cooperates with other oncogenic changes to promote urothelial tumorigenesis and progression. Inactivation of the tumor suppressor phosphatase and tensin homolog on chromosome ten (PTEN) is associated with squamous cancers independent of anatomic site, and found in a subset of MI BLCa. Therefore, we undertook studies to identify the extent to which FOXA1 and PTEN inactivation cooperate to promote progression to MI BLCa.
INTRODUCTION AND OBJECTIVES: BCG immunomodulatory effect has proven effective in high-grade non-muscle invasive bladder cancer (NMIBC), but refractory patients are at risk of muscle-invasive disease. We explored the efficacy of intravesical Thalidomide (immunemodulatory, anti-inflammatory, and anti-angiogenic) added to BCG using an immune competent autochthonous orthotopic NMIBC animal model. METHODS: Female Fischer 344 rats, 7 weeks of age, received once every 15 days, for 4 times, a dose of 1.5 mg/kg of n-methyl-nnitrosourea (MNU) intravesically. The rats were randomized in 4 groups (n¼10 per group) to receive intravesical treatment once a week for 6 weeks as follows: MNU cancer (0.2 ml vehicle), BCG (2 x 10 6 CFU of Moreau strain in 0.2 ml), Thalidomide (20mg/kg in 0.2 ml) and BCG-Thalidomide in 0.2 ml. At week 16, bladders were collected for histopathology, cell turnover index by immunohistochemistry and immunoblotting quantification of 4E-BP1 and p70S6K1 for downstream mTOR proliferation signaling and HIF and VEGF for angiogenesis pathway.
RESULTS: Treatments were responsible for favorable histopathology, cell turn over and down-regulation of p70S6K1, HIF-1 and VEGF. Optimal histopathology and cell turnover index was seen in Thalidomide-BCG association. All treatments reduced the action of p70S6K1 but not 4E-BP1 supporting that these proteins regulation occur independently on mTOR pathway in NMIBC.
CONCLUSIONS: Intravesical BCG-Thalidomide might represent a significant increment in NMIBC treatment, suggesting p70S6K1, HIF-1 and VEGF as potential molecular target candidates in a clinically relevant immune competent NMIBC model. Hosni Salem*, Mona Abdel Hamid, Doha El-Sayed Ellakwa, Hanan Fouad, Cairo, Egypt INTRODUCTION AND OBJECTIVES: Proteomic patterns in body fluids gain increasing importance as a new tool for the identification of novel, highly sensitive diagnostic markers for the detection of cancer. One promising approach in the search for useful bladder cancer biomarkers is to study the urine proteome during the occurrence of the disease. No previous reports on assessment of ApoA1 and ApoA2 protein in serum or tissue of bladder cancer patients. The aim of our study to Identify and assess the expression of ApoA1 and ApoA2 protein in urine samples of bladder cancer patients and to validate results by correlations with analysis of urinary bladder tissue and blood samples. Also to Correlate the results with histopathology findings, and the clinical picture METHODS: Thirty two patients admitted to the urology department were enrolled in the study; 22 were histologically diagnosed as bladder cancer patient whereas the remaining 10 patient were diagnosed as cystitis. Ten healthy control subjects were also included in the study. Morning voided urine sample and Ten ml blood sample were collected from each patient. Urine and blood samples were transported to the laboratory on ice., and were separated by centrifugation and stored at -80 C till the time of laboratory assays. One gm from suspected tissue lesions were collected during cystoscopy from suspected bladder cancer patients. Western blot technique was used to measure ApoA1 and ApoA2 protein in the serum and urine of the three groups in addition to the tissue of bladder cancer.
RESULTS: ApoA1 & ApoA2 expression in voided urine was significantly higher in malignant group than cystitis (benign) group than normal healthy group (P < 0.05). ApoA1 & ApoA2 expression in the serum of cancer patients showing no significant difference from normal control group. ApoA1 &ApoA2 in urine and tissue of the malignant groups were nearly expressed in the same ratio. There was no e860 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 
